These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11223552

  • 1. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
    Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, Aizawa T, Watanabe T, Uda Y, Tanigawara Y, Sasaki Y.
    Jpn J Cancer Res; 2001 Feb; 92(2):220-30. PubMed ID: 11223552
    [Abstract] [Full Text] [Related]

  • 2. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

  • 3. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
    Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI.
    Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
    [Abstract] [Full Text] [Related]

  • 4. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
    Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM.
    Clin Cancer Res; 1997 Nov; 3(11):2005-15. PubMed ID: 9815591
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.
    J Clin Oncol; 2001 Feb 01; 19(3):832-42. PubMed ID: 11157037
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ.
    J Clin Oncol; 2000 Mar 01; 18(5):1124-34. PubMed ID: 10694566
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB.
    J Clin Oncol; 2001 Jun 15; 19(12):2983-93. PubMed ID: 11408493
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
    Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL.
    Br J Cancer; 2005 Jul 11; 93(1):46-53. PubMed ID: 15942626
    [Abstract] [Full Text] [Related]

  • 10. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E, Haeri A, Vali AM, Ostad SN, Dadashzadeh S.
    J Pharm Pharm Sci; 2012 Jul 11; 15(4):568-82. PubMed ID: 23106959
    [Abstract] [Full Text] [Related]

  • 11. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 12. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R, Mayer LD.
    Cancer Res; 1997 Dec 01; 57(23):5246-53. PubMed ID: 9393743
    [Abstract] [Full Text] [Related]

  • 13. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
    Uchiyama-Kokubu N, Watanabe T, Nakajima M.
    Anticancer Drugs; 2000 Aug 01; 11(7):583-90. PubMed ID: 11036963
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM.
    J Clin Oncol; 1996 Feb 01; 14(2):610-8. PubMed ID: 8636778
    [Abstract] [Full Text] [Related]

  • 15. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
    Krishna R, St-Louis M, Mayer LD.
    Int J Cancer; 2000 Jan 01; 85(1):131-41. PubMed ID: 10585596
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Jan 01; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 17. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
    Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM.
    J Clin Oncol; 2000 Nov 01; 18(21):3677-89. PubMed ID: 11054441
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
    Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF.
    J Clin Oncol; 2001 Mar 15; 19(6):1589-99. PubMed ID: 11250987
    [Abstract] [Full Text] [Related]

  • 19. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T.
    Cancer; 2001 Sep 15; 92(6):1577-90. PubMed ID: 11745237
    [Abstract] [Full Text] [Related]

  • 20. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
    Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA.
    J Clin Oncol; 1999 Sep 15; 17(9):2831-9. PubMed ID: 10561359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.